The effects of other oral, brain-penetrant NMDA receptor antagonists that bind to the NR2B receptor subunit (including TXT-0300, Traxion Therapeutics; and MK-0657, Merck) have also been ...

Announcement follows FDA's February 2025 decision to grantradiprodil Breakthrough Therapy designation Company remains on track to initiate Phase 3 pivotal trial ofradiprodil ...